



# Biotech Daily

Friday September 4, 2015

*Daily news on ASX-listed biotechnology companies*

- \* **ASX DOWN, BIOTECH EVEN: ANALYTICA UP 20%  
- COMPUMEDICS DOWN 11%**
- \* **VICTORIA AWARDS \$26m INFRASTRUCTURE SUPPORT GRANTS**
- \* **JAPAN TO APPROVE MESOBLAST, JCR JR-031 FOR GVHD**
- \* **OPTISCAN, MR SOLUTIONS LAUNCH CELLIVE IMAGING SYSTEM**
- \* **STARFISH DILUTED TO 44% OF DORSAVI**
- \* **REGENEUS TO RELEASE 48m ESCROW SHARES**
- \* **MMJ TO RELEASE 7.2m ESCROW SHARES**

## MARKET REPORT

The Australian stock market fell 0.25 percent on Friday September 4, 2015 with the ASX200 down 12.8 points to 5,040.6 points.

Fourteen of the Biotech Daily Top 40 stocks were up, 14 fell, 10 traded unchanged and two were untraded.

Analytica was the best, up 0.1 cents or 20 percent to 0.6 cents with 100,000 shares traded, followed by Circadian up 10 percent to 22 cents with 124,355 shares traded.

Mesoblast climbed 7.7 percent; Polynovo was up 4.8 percent; Anteo, Bionomics, Neuren and Oncosil were up more than three percent; Actinogen and Antisense rose two percent or more; Admedus and Ellex were up more than one percent; with CSL, Sirtex, Starpharma and Resmed up by less than one percent.

Compumedics led the falls, down three cents or 11.1 percent to 24 cents with 106,286 shares traded.

Prana lost 7.1 percent; Acrux fell 4.9 percent; Cellmid, Clinuvel, Impedimed, Medical Developments, Prima and Reva were down more than three percent; Benitec, Biotron and Osprey shed two percent or more; Nanosonics and Tissue Therapies were down more than one percent; with Cochlear down 0.4 percent.

## VICTORIA GOVERNMENT

The Victoria Government has awarded \$26 million to 10 medical research institutes under the Operational Infrastructure Support Program.

A State Government media release said that the funding supported laboratories to run their facilities and equipment.

The media release said that the Walter and Eliza Hall Institute of Medical Research would receive \$6,210,270; the Murdoch Children's Research Institute \$4,042,845; the Baker IDI Heart and Diabetics Institute \$3,425,514; the Florey Institute of Neuroscience & Mental Health \$3,138,860; the Burnet Institute \$2,752,991; the Hudson Institute of Medical Research \$2,322,570; the St Vincent's Institute, including the Bernard O'Brien Institute \$1,649,706; the Olivia Newton-John Cancer Research Institute \$1,069,839; the Centre for Eye Research Australia \$1,036,419; and the Bionics Institute \$450,986.

## MESOBLAST

Mesoblast says that the Japan Ministry of Health, Labour and Welfare has recommended approval of JR-031 for acute graft versus host disease.

Mesoblast said that JR-031 was an allogeneic mesenchymal stem cell product developed by Japanese partner JCR Pharmaceuticals Co and marketing approval was expected "in the near future".

Mesoblast said that acute graft versus host disease was a severe complication arising from haematopoietic cell transplants, including bone marrow transplants, which JCR had been developing in Japan using technology under a licence from Mesoblast.

The company acquired the mesenchymal stem cell program and JCR as a partner when it bought the stem cell program from Osiris in 2013 (BD: Oct 11, 2013).

Mesoblast quoted JCR saying that clinical trials demonstrated the efficacy and safety of JR-031 which led to their filing for a marketing approval in September 2014.

Mesoblast said it was entitled to receive milestone payments on JR-031 product regulatory approvals, as well as royalties and other payments at pre-defined thresholds of cumulative net sales.

Mesoblast was up 24 cents or 7.7 percent to \$3.34 with 431,221 shares traded.

## OPTISCAN

Optiscan says that its exclusive global distributor Guildford, Surrey-based MR Solutions has launched the Celllive imaging system using its microscopy technology.

Optiscan said that the Celllive imaging platform based on its confocal microscope technology had real-time, fluorescence microscopic imaging for pre-clinical research applications and was launched at the World Molecular Imaging Congress in Hawaii.

The company said that the system offered "unique insights into living animal biology with key applications in cancer research, neuroscience and regenerative medicine, including stem cell research", with its miniaturized imaging probes were placed directly into contact with the tissue to be imaged.

Optiscan said that the system had full three-dimensional (3D) imaging capabilities with integrated analysis and measurement tools, as well as "spectral imaging capabilities, enabling, for example, separate imaging of multiple molecular labels in a single animal".

The company said that the miniaturized imaging probes could provide ultra-high resolution of less than one micron and automated 3D imaging collection, display and analysis.

Optiscan said that more than 1,000 pre-clinical research laboratories could use Celllive.

Optiscan was unchanged at five cents.

### [DORSAVI](#)

The Starfish Technology Fund says it holds 60,597,345 shares in Dorsavi and has been diluted from about 50.0 percent to about 44.0 percent in the recent placement.

In two substantial shareholder notices filed yesterday by Starfish and Dorsavi, the companies implied that they had acquired 1,000,000 shares for \$356,376 or 35.6 cents a share, but Starfish director Dr Michael Panaccio told Biotech Daily that there was no change in the holding other than the dilution by the recent capital raising and the filings were due to legal requirements.

Dr Panaccio said Dorsavi had issued the 1,000,000 shares to staff under the Dorsavi employee share ownership plan.

In August, Dorsavi said it had raised \$4,000,000 through a placement at 26 cents a share and hoped to raise up to \$3.2 million through a one-for-10 rights offer at the same price, with Starfish applying for its full entitlement (BD: Aug 26, 2015).

Dorsavi was untraded at 26 cents.

### [REGENEUS](#)

Regeneus says that 48,066,732 shares held by 39 investors and 5,114,281 options will be released from ASX escrow on September 21, 2015.

According to its most recent Appendix 3B new issue announcement, Regeneus has 103,305,383 shares quoted on the ASX.

Regeneus was up one cent or 8.7 percent to 12.5 cents.

### [MMJ PHYTOTECH](#)

MMJ says it will release 7,200,000 shares from ASX escrow on September 17, 2015.

MMJ said that following the release of the shares, a total of 42,916,666 securities, including fully paid ordinary shares, performance rights and options, would remain subject to a 24 month escrow period from the date of the company's listing on September 17, 2014.

The company said that a further 52,530,000 shares were subject to various voluntary escrow restrictions issued in connection with the merger between MMJ Bioscience and Phytotech.

According to its most recent Appendix 3B new issue announcement, MMJ has 103,305,383 shares quoted on the ASX.

MMJ fell half a cent or 1.6 percent to 31.5 cents.